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ABSTRACT 
Objective: The main aim of the present research work was to formulate fast dissolving tablets of famotidine by direct compression method and to 
evaluate the effect of synthetic super disintegrating agent on drug release pattern.  
Methods: The fast dissolving tablets were prepared by using crospovidone, croscarmellose sodium, sodium starch glycolate as superdisintegrants 
(2, 4 and 6 %w/w), mannitol 20 % and microcrystalline cellulose (44, 46 and 48 % w/w) as a directly compressible vehicle. All the prepared tablets 
were evaluated for hardness, friability, drug content uniformity, weight variation, disintegrating time, wetting time and in vitro drug release studies.  
Results: All the prepared fast dissolving tablets formulations were within the Pharmacopoeial standards limits. Based on in vitro drug release 
studies (>90 % within 30 min), the optimised formulations were optimised tested for the short term stability (at 40 ˚C/75% RH for 3 mo) and drug 
excipient interaction (fourier transform infrared spectroscopy).  
Conclusion: Hence, formulation prepared with 6 % w/w of crosspovidine and 44 % w/w of microcrystalline cellulose as emerged as the overall 
best formulation (>90 % within 30 min) compared to marketed product (>70 % within 30 min). Short-term stability studies on the formulations 
indicated that there are no significant changes in drug content and in vitro drug release (p<0.05). 
Keywords Famotidine, Croscarmellose sodium, Crosspovidine, Sodium starch Glycolate, Fast dissolving tablets 




Oral routes of drug administration is the most popular route for 
systemic effects due to its ease of ingestion, pain, avoidance, 
versatility and most importantly patient compliance. As solid 
formulations do not require any sterile conditions they are less 
expensive [1]. Famotidine is a propanimidamide and histamine H2-
receptor antagonist with antacid activity. As a competitive inhibitor 
of histamine H2-receptors located on the basolateral membrane of 
the parietal cell, famotidine reduces basal and nocturnal gastric acid 
secretion, resulting in a reduction in gastric volume, acidity, and 
amount of gastric acid released in response to various stimuli. The 
drug is 40-45 % absorbed orally but it undergoes minimal 
metabolism on first pass through the liver. Famotidine is 
metabolized in the liver to famotidine S-oxide (S-famotidine). They 
also inhibit gastric acid secretion stimulated by food, betazole, 
pentagastrin, caffeine, insulin and physiological vagal reflex. 
Famotidine is used in the treatment of peptic ulcer disease and 
gastroesophageal reflux disease [2-4]. Thus, famotidine is better 
option for the development of immediate release tablets [5, 6]. The 
purpose of the present research work was to develop and 
characterize immediate release tablets of famotidine using various 
synthetic superdisintegrants such as crospovidone (CP), 
croscarmellose sodium (CCS), sodium starch glycolate (SSG) with 
mannitol to release the medicament and mask bitter taste [7-9]. 
Fasting dissolving tablets (FDTs) helps in immediate release of 
medicament, leading to an increase in bioavailability of the drug and 
quick onset of pharmacological action can take place [10-14]. 
MATERIALS AND METHODS 
Materials  
Famotidine, crospovidone, croscarmellose sodium and sodium 
starch glycolate were purchased from Yarrow chem. product, 
Mumbai, India. Mannitol was purchased from Fisher scientific 
laboratory, Andhra Pradesh, India. Microcrystalline cellulose was 
purchased from Chemica-biochemica reagents, Mumbai, India. All 
other reagents and chemicals were of analytical grade. 
 
Table 1: Formulation of famotidine fast dissolving tablets 
S. No. Ingredients (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 
1. Famotidine 20 20 20 20 20 20 20 20 20 
2. Sodium starch glycolate  4 8 12 - - - - - - 
3. Croscarmellose sodium - - - 4 8 12 - - - 
4. Crospovidone - - - - - - 4 8 12 
5. Mannitol  20 20 20 20 20 20 20 20 20 
6. Microcrystalline cellulose 51 47 43 51 47 43 51 47 43 
7. Magnesium stearate 5 5 5 5 5 5 5 5 5 
 Total weight 100 100 100 100 100 100 100 100 100 
 
Methods 
Preparation of famotidine FDTs  
Each tablet containing 20 mg famotidine were prepared by using 
direct compression method with 50 tablets for batch. The 
compositions of various formulations of the tablets with F1 to F9 
were listed in table 1. For preparation of powder blend, pure drug 
famotidine and superdisintegrants SSG, CCS and CP were passed 
through sieve No. 40 # and mixed well for 10 min in a glass motor 
and pestle. To the above add microcrystalline cellulose after passing 
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through sieve No. 40 # and blended thoroughly for 5 min to make 
powdered blend. This powder was lubricated with sufficient amount 
of magnesium stearate after passing through sieve No. 80 # [15]. All 
the materials were directly compressible so this uniformly mixed 
blend was compressed into tablets of 100 mg weight on 12 station 
tablet compression machine (Rimek tablet MINI press, karnavathi 
engineering Pvt. Ltd. Gujarat, India) using 8 mm flat round punches 
with 2-4 kg/cm2 
Evaluations 
hardness. 
Evaluation of pre-compression parameters  
Pre-compression parameters such as angle of repose, bulk density 
and tap density, Carr‘s compressibility index and Hausner‘s ratio 
were determined [16, 17].  
Angle of repose  
It was determined by funnel method. The frictional forces in a loose 
powder or granules can be measured by angle of repose. This is the 
maximum angle possible between the surface of a pile of powder or 
granules and the horizontal plane. The powder was allowed to flow 
through the funnel fixed to a stand at definite height. The angle of 
repose (θ) was calculated by measuring the height (h) and radius® of 
the heap of granules, using Eq. 1.  
 
Bulk density  
The bulk density was determined by pouring the blend into a 
graduated cylinder of density apparatus. The bulk volume (V0) and 
the weight of powder (M) were determined. The bulk density (ρo) 
can be calculated using the formula given in Eq. 2. 
 
Tapped density  
The bulk density apparatus was allowed to tap for a fixed time. The 
minimum volume required in the cylinder (Vf) and weight of the 
blend (M) were obtained. The tapped density (ρ f) can be calculated 
using the formula given in Eq. 3. 
 
Carr’s compressibility index  
The flow ability of powder can be evaluated by comparing the bulk 
density and tapped density of powder and the rate at which it packed 
down. The Carr’s compressibility index is calculated by using the Eq. 4. 
 
Hausner’s ratio  
It is an indirect index of easy of powder flow. It is calculated by using 
Eq.5. 
 
Compatibility studies  
The compatibility studies were performed using fourier transform 
infrared spectroscopy (FTIR), differential scanning calorimetric 
studies (DSC), X-ray diffraction studies (XRD) and scanning electron 
microscope (SEM).  
Evaluation of post-compression parameters  
Post-compression parameters such as weight variation, thickness, 
hardness, friability, water absorption ratio, wetting time, 
disintegration test, in vitro dispersion time, content uniformity and 
in vitro dissolution study were determined.  
Weight variation  
Randomly 20 tablets were taken from each batch and their weight 
was determined individually and collectively on a digital weighing 
balance. The average weight of the tablet was determined from the 
collective weights [18]. 
Thickness  
Randomly 10 tablets from each formulation were taken and their 
thickness was measured using a Vernier callipers and the reading 
was recorded in millimetres [19]. 
Hardness  
Three tablets were randomly picked from each formulation batch 
and the mean and standard values were calculated [19]. Hardness of 




A sample of whole tablets corresponding to about 6.5 g was weighed 
and the initial weight was recorded (Wo) and placed in Roche 
friabilator and rotated at the speed of 25 rpm for 100 revolutions [15]. 
Then tablets were removed from the friabilator, dusted off the fines 
and again weighed and the final weight was recorded (Wf). Percentage 
friability was calculated by using the formula given in Eq. 6.  
 
Wetting time and water absorption ratio  
A piece of tissue paper folded twice and placed in small petri dish 
containing 10 ml of water. Initially tablet was weighed (Wb), placed 
on the paper and time for complete wetting was measured as 
wetting time [19]. The wetted tablet was weighted (Wa). Water 
absorption ratio, R, was calculated using the formula given in Eq. 7.  
 
Disintegration test  
The disintegration time was performed using USP disintegration test 
apparatus with 0.1 N HCl medium at 37±0.5˚C. A tablet was placed in 
each of six tubes of apparatus and one disc was added to each tube. 
The time was recorded when all the fragments of the disintegrated 
tablet (6 tablets) passed through the screen of the basket [18].  
Content uniformity  
The drug content was determined by taking 10 dosage units at 
random and powdered. The blend equivalent to 20 mg of famotidine 
was weighed and dissolved in 100 ml of 0.1 N HCl solution, stirred 
for 15 min and filtered. Absorbance was measured at 265 nm using a 
UV-Visible double beam spectrophotometer (Cary 60, Agilent 
technologies, Germany) [5]. 
In vitro dissolution studies  
In vitro dissolution studies of famotidine were performed in USP XXIII 
dissolution testing apparatus II (paddle type). The dissolution test was 
performed using 900 ml of 0.1 N HCl (pH-1.2), at 37±0.5 ˚C with 50 rpm 
speed. A sample of 5 ml solution was withdrawn from the dissolution 
apparatus at 5, 10, 15, 30, 45 and 60 min respectively and replaced with 
5 ml of fresh dissolution medium. The samples were filtered through 
Whatmann filter paper (No. 41, Ash less circles 150 mm) and measured 
after suitable dilutions using spectrophotometrically at 265 nm. All the 
dissolution tests were carried out in triplicates. Cumulative percentage of 
drug release was drug release was calculated using an equation obtained 
from a standard curve [5]. 
Statistical analysis  
All the values are expressed as mean±standard deviation (SD). The t-
test was used to study the significznce differnce between the control 
and test at 0.05% of level of significance. All the values are 
represented in three determinents. The value less than 0.05 was 
taken as no significance difference. 
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RESULTS AND DISCUSSION 
In the present investigation, FDT of famotidine were prepared by 
using synthetic superdisintegrants such as crosspovidone, cross 
carmellose sodium and sodium starch glycolate. 
Identification of pure drug  
Physical characterization studies stated that famotidine is white to pale 
yellow crystalline powder with bitter taste. The melting point of 
famotidine was found to be in the range of 162–164 °C when tested 
using capillary method in melting point apparatus in triplicate, which 
complies with the standard values in the official monograph as per USP-
NF. It was found that famotidine is practically insoluble in water, but 
soluble in organic solvents like acetone, glacial acetic acid.  
Identification of the drug was done from absorption maxima, IR and 
DCS studies. Absorption maxima of 265 nm confirmed that the drug 
was pure famotidine as it was previously mentioned in associated 
literature [5]. The spectra were recorded for pure drug famotidine 
shown in fig. 1. 
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Fourier transform infrared spectroscopy 
Drug polymer interaction was studied by FTIR analysis. The FTIR 
spectra of the pure drug famotidine, mannitol, crosspovidone and 
optimised formulation F8 were shown in the fig. 2. The FTIR spectrum 
of pure drug showed a characteristic peak of alcohol (OH) stretching 
vibration at 3400 cm-1 and alkynes stretching vibration at 3300 cm-1. 
An asymmetric stretching peak at 2100 cm-1 and symmetric stretching 
peak at 1600 cm-1 indicating the drug was pure. The FTIR spectrum of 
mannitol showed absorption band nearly at 3300 cm-1 (N-H), 2800 cm-
1 (C-H) and 1400 cm-1 (C=C) stretching vibration. The FTIR spectrum 
of crosspovidone showed absorption band nearly at 3400 cm-1 (OH), 
2900 cm-1 (C=O) and 1300 cm-1
Differential scanning calorimetric studies 
 (C=C) stretching vibration. The same 
peaks were reported in the optimised formulation F8 containing 8% of 
crosspovidone and mannitol. There was no change or shifting of 
characteristic peaks of famotidine tablets, suggested that there was no 
significant drug polymer interaction which indicates the stable nature 
of drug inside the formulation. 
The DSC thermograph of pure famotidine, mannitol, crosspovidone 
and optimised formulations F8 shown in fig. 3. The DSC thermograph 
of famotidine showed a sharp endothermic peak at 163.8 °C due to 
melting point of the drug with the enthalpy value of 34.1 mJ/mg. This 
shows that the drug considered for the research is in pure form. The 
melting peak of optimised formulation F8 was shifted to 164.1 °C with 
16.49 mJ/mg enthalpy value. The change in melting endotherm of drug 
may be due to mixing process which lowers purity of each component, 
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XRD studies 
The XRD pattern of famotidine, mannitol, crosspovidone, optimised 
formulations F8 were shown in fig. 4. The XRD pattern of famotidine 
showed characteristic sharp intensity diffraction peaks at 2θ 
equivalent to 11.39 °, 15.49 °, 17.63 °, 20.65 °, 23.70 ° and 31.9 ° 
which reflects the crystalline nature of drug. The XRD diffractogram 
of the optimised formulation F8 with 8 % CP showed reduction in 
peak intensity when compared to the famotidine which was 
negligible. The results showed that the formulation F8 converted the 
drug which is a strong crystal habit into a totally amorpous one and 
was supported by DSC. As a result of amorphisation and substantial 
increase in surface area, drug particles acquired high internal energy 






Fig. 4: XRD studies of a) Famotidine, b)Mannitol, c) Crosspovidone and d) Optimised formulation F8 containing 8% of crosspovidone 
 
SEM analysis 
The SEM analysis of famotidine, mannitol, crosspovidone, optimised 
formulations F8 shown in fig. 5. The microphotograph of famotidine 
showed shaped crystalline structure. In the optimised formulations FR4 
and FR8, the crystallinity of the drug was lost that indicate the molecular 
mixing of the drug with CCS and fenugreek seed mucilage powder. 
Evaluation of pre-compression studies 
Direct compression technique was used for the preparation of the 
FDT. Flow characteristics of the material being compressed are 
important parameters and hence studies were undertaken for the 
evaluation of flow characteristics of the lubricated blend used in the 
present study. The results of flow properties of the prepared 
lubricated blends are shown in table 2. As the angle of repose values 
were within the range of 21.08° to 27.15° for F1 to F9 formulations 
respectively, which indicates excellent to good flow properties. The 
compressibility index of all the formulations were within the range 
of 11.17–14.56 % respectively, with good compressibility index as 
all the values are within 15 % results in good to excellent flow 
properties and which describes the frictional and cohesive 
interactions of the polymers in the formulation. Hausner’s ratio of all 
the formulations was in the range of 1.12 to 1.24 which indicated 
good flow characteristics for the prepared lubricated blends, as all 
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Fig. 5: SEM analysis of a) Famotidine, b) Mannitol, c) Crosspovidone and d) Optimised formulation F8 containing 8 % of crosspovidone 
 
Table 2: Pre-compression properties of prepared formulations 
Formulation code Angle of repose Bulk density(gm/cm3 Tapped density(gm/cm) 3 Carr’s index ) Hausner’s ratio 
F1 26.25±0.64 0.39±0.03 0.46±0.24 13.21 1.17 
F2 25.41±0.48 0.39±0.12 0.47±0.19 12.02 1.20 
F3 22.73±0.46 0.38±0.09 0.46±0.24 14.56 1.24 
F4 26.76±0.32 0.37±0.17 0.45±0.12 11.55 1.18 
F5 22.14±0.66 0.38±0.15 0.41±0.14 13.75 1.10 
F6 21.84±0.89 0.40±0.16 0.45±0.16 11.17 1.12 
F7 27.15±0.42 0.38±0.12 0.46±0.21 12.13 1.24 
F8 22.21±0.36 0.37±0.16 0.47±0.18 13.17 1.12 
F9 21.08±0.32 0.36±0.14 0.43±0.12 14.13 1.23 
All the values are expressed as mean±SD where number of experiments (n=3). 
 
Evaluation of post-compression parameters 
Tableting characteristics of the famotidine FDTs  
Prepared tablets were evaluated for weight variation, hardness, 
friability, wetting time, water absorption ratio, disintegration time 
and assay and results are given in table 3 and 4. 
All the prepared famotidine FDT are greater than 100 mg and are 
well within the range of 5 % and hence qualify the test for 
uniformity of weight. The thickness of all the formulations was in the 
range of 0.83 to 0.98 mm and hardness of all the formulations was in 
the range of 3 to 4 kg/cm2
The wetting time of all the formulations was in the range of 37 to 45 
sec. The water absorption ratio of all the formulations was in the 
range of 83.2 to 99.6 sec. The disintegration time of all the 
formulations was in the range of 85-120 sec. Assay was found to be 
in the range of 98.94 to 101.29 % of the stated amount of famotidine. 
Thus, famotidine FDT prepared with the selected superdisintegrants 
were regarded as good quality fulfilling the official and other 
requirements of tablets. 
. The percentage weight loss in the 
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Table 3: Physicochemical properties of the famotidine FDT 
S. No. Weight variation (kg/cm2) Thickness (mm)* Hardness (kg/cm** 2) Friability (%)** *** 
F1 100.08±0.11 0.83±0.14 3-4 0.39 
F2 101.07±0.12 0.98±0.16 3-4 0.42 
F3 100.17±0.14 0.92±0.18 3-4 0.38 
F4 100.97±0.13 0.91±0.24 3-4 0.45 
F5 100.83±0.12 0.86±0.23 3-4 0.37 
F6 101.01±0.11 0.9240.15 3-4 0.35 
F7 100.95±0.14 0.91±0.18 3-4 0.42 
F8 100.21±0.12 0.89±0.22 3-4 0.40 
F9 101.01±0.18 0.93±0.15 3-4 0.35 
Values are expressed as mean±SD where * n=20; **n=5; ***n≈6.5 gm of total weight. 
 
Table 4: Physicochemical properties of the famotidine FDT 
S. No. Wetting time (sec) Water absorption ratio (%)* Disintegration  time (sec)*  * Drug content (%)** 
F1 39±0.14 87.9±0.41 108±1.61 99.86±0.14 
F2 38±0.16 89.6±0.25 101±1.24 99.71±0.40 
F3 41±0.18 96.2±0.18 95±1.22 98.94±0.68 
F4 39±0.12 95.6±0.29 85±1.44 100.07±0.12 
F5 43±0.22 96.8±0.36 120±1.35 99.88±0.43 
F6 37±0.19 99.5±0.15 101±1.32 100.16±0.15 
F7 45±0.22 83.2±0.24 116±1.06 99.27±0.48 
F8 39±0.15 98.7±0.39 91±1.03 101.29±0.11 
F9 37±0.19 99.6±0.43 107±1.32 100.15±0.13 




Fig. 6: Cummulative % drug release of famotidine pure drug and formulations F1 to F9 prepared with synthetic superdisintegrants (n=3, 
mean±SD) 
 
In vitro dissolution studies 
The in vitro dissolution studies of fast dissolving tablets were 
conducted in simulated gastric fluid 0.1 N HCl for 1 h. The results of 
the drug release studies of all the prepared formulations are shown 
in fig. 6. 
The F1-F9 famotidine FDT formulations prepared with different 
ratios of synthetic superdisintegrants, have shown release profile 
similar >66% drug release in 1 h.  
The drug release from F1, F2 and F3 were composed of sodium 
starch glycolate 4 %, 8 % and 12 % was found to be 90.32, 94.41 and 
95.04 % in 60 min. The drug release from F4, F5 and F6 were 
composed of croscarmellose sodium 4 %, 8 % and 12 % was found 
to be 85.62, 92.47 and 95.32 in 60 min. The drug release form 
formulations F7, F8 and F9 were composed of crosspovidone was 
found to be 79.62, 99.98 and 99.89 in 60 min.  
From all the above studies formulation F8 prepared with 8 % of 
crosspovidone showed more than 70 % and 95 % of drug release 
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within 5 min and 1 hour, might be due to low water uptake and 
more gelling nature of CCS, SSG than CP [20], which is shown to have 
low swelling efficiency, high water uptake capacity and spongy 
nature, which yield porous tablets that disintegrate in fraction of 
seconds. Hence, formulation F8 is selected as the best formulation 
among all the other formulations. 
The in vitro drug release profiles of famitidine were applied on 
various kinetic models in order to evaluate the mechanism of drug 
release. The different kinetic models evaluated were zero order, first 
order, Higuchi, Hixson-Crowell. The data obtained were also put in 
Korsmeyer-Peppas model in order to find out n value, which 
describes the drug release mechanism.  
All the formulations followed First order release with Fickian 
mechanism of drug release, due to the dominant erosion pattern, 
results were given in table 5. This may be due to the use of 
synthetic superdisintegrants in these formulations exhibited 
dominant erosion pattern with burst release of the drug from the 
formulation. 
 

















Pure Drug 0.609 0.682 0.855 0.866 0.658 0.269 Fickian 
F1 0.680 0.929 0.900 0.968 0.864 0.249 Fickian 
F2 0.602 0.892 0.855 0.969 0.808 0.223 Fickian 
F3 0.436 0.826 0.712 0.958 0.689 0.121 Fickian 
F4 0.687 0.925 0.909 0.961 0.860 0.284 Fickian 
F5 0.635 0.932 0.870 0.981 0.856 0.214 Fickian 
F6 0.460 0.816 0.739 0.877 0.689 0.151 Fickian 
F7 0.459 0.759 0.726 0.952 0.654 0.123 Fickian 
F8 0.472 0.945 0.738 0.981 0.825 0.124 Fickian 
F9 0.430 0.877 0.700 0.982 0.819 0.108 Fickian 
 
Comparative studies 
The famotidine pure drug, optimised formulations F8 with 8 % 
crosspovidone was compared with the marketed product. The drug 
release profiles were shown in fig. 7. The drug release was found to 
be 21.67 % for pure drug in 5 min, where as 54.61 % and 73.82 % 
for marketed product and optimised formulations F8.  
Hence, the in vitro drug release for the optimised formulation F8 was 
found to be better than the marketed product. 
  
 




The present study was carried out to develop the fast dissolving 
tablets of famotidine by using various superdisintegrants at different 
ratios in comparison with marketed product. The formulations 
prepared with 8 % w/w concentration of CP F8 for fast dissolving 
tablets were found to be more suitable than the formulation 
prepared with other synthetic superdisintegrants and gave 
maximum drug release (%) within 5 min. It was found that the 
release rate was found to be more influenced by crospovidone 
superdisintegrant and the concentration of the disintegrant 
employed in the preparation of the tablets. The optimised 
formulation F8 drug release with crospovidone is slightly greater 
than that of the other synthetic superdisintegrant. 
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